Department of Internal Medicine, University of Health Sciences, Antalya Training and Research Hospital, Antalya, Turkiye.
Department of Endocrinology and Metabolism, University of Health Sciences, Antalya Training and Research Hospital, Antalya, Turkiye.
J Coll Physicians Surg Pak. 2023 Aug;33(8):842-846. doi: 10.29271/jcpsp.2023.08.842.
To determine Omentin-1 in hypothyroid patients with autoimmune thyroiditis compared to controls.
Observational study. Place and Duration of the Study: Department of Internal Medicine and Endocrinology, University of Health Sciences, Antalya Training and Research Hospital, Turkiye, between August 2017 and March 2020.
The study included 63 newly diagnosed hypothyroid patients with autoimmune thyroiditis and 40 healthy volunteers. Body mass index, fasting blood glucose, homeostasis model assessment for insulin resistance, lipid profile, thyroid function tests, thyroid autoantibodies, and omentin-1 levels were determined before and after treatment with levothyroxine sodium in all participants.
Omentin-1 was significantly higher in the control subjects [15.05 (12.12-18.06) ng/ml] than in the hypothyroid patients with autoimmune thyroiditis [3.04 (2.39-3.76) ng/ml, p<0.001]. There was no significant difference in omentin-1 level in patients who achieved euthyroidism by treatment (p=0.26). In correlation analysis, serum omentin-1 level was found to correlate negatively with thyroid-stimulating hormone (r=-0.27, p=0.006), anti-thyroid peroxidase (r=-0.32, p=0.001), and anti-thyroglobulin antibodies (r=-0.26, p=0.007), whereas it correlated positively with free triiodothyronine (r=0.22, p=0.021) and free thyroxine (r=0.24, p=0.012).
Lower omentin-1 levels in hypothyroid patients with autoimmune thyroiditis and its negative correlation with thyroid-stimulating hormone suggest that omentin-1 may play some role in hypothyroidism and autoimmune thyroiditis.
Hypothyroidism, Chronic autoimmune thyroiditis, Omentin-1.
与对照组相比，确定自身免疫性甲状腺炎伴甲状腺功能减退症患者的网膜素-1水平。
观察性研究。研究地点和时间：土耳其安塔利亚健康科学大学安塔利亚培训与研究医院内科和内分泌科，2017 年 8 月至 2020 年 3 月。
该研究纳入了 63 例新诊断的自身免疫性甲状腺炎伴甲状腺功能减退症患者和 40 名健康志愿者。所有参与者均在接受左甲状腺素钠治疗前后测定体重指数、空腹血糖、胰岛素抵抗评估的稳态模型、血脂谱、甲状腺功能、甲状腺自身抗体和网膜素-1水平。
对照组网膜素-1水平明显高于自身免疫性甲状腺炎伴甲状腺功能减退症患者[15.05（12.12-18.06）ng/ml] [3.04（2.39-3.76）ng/ml，p<0.001]。治疗后达到甲状腺功能正常的患者网膜素-1水平无显著差异（p=0.26）。在相关性分析中，血清网膜素-1水平与促甲状腺激素（r=-0.27，p=0.006）、抗甲状腺过氧化物酶（r=-0.32，p=0.001）和抗甲状腺球蛋白抗体（r=-0.26，p=0.007）呈负相关，而与游离三碘甲状腺原氨酸（r=0.22，p=0.021）和游离甲状腺素（r=0.24，p=0.012）呈正相关。
自身免疫性甲状腺炎伴甲状腺功能减退症患者网膜素-1水平较低，与促甲状腺激素呈负相关，提示网膜素-1可能在甲状腺功能减退症和自身免疫性甲状腺炎中发挥一定作用。
甲状腺功能减退症、慢性自身免疫性甲状腺炎、网膜素-1。
